|
|
Volumn 296, Issue 5567, 2002, Pages 474-475
|
|
Biomedicine: Back to an aspirin a day?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CELECOXIB;
CYCLOOXYGENASE 1 INHIBITOR;
CYCLOOXYGENASE 2 INHIBITOR;
ETODOLAC;
ETORICOXIB;
MELOXICAM;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
ROFECOXIB;
BIOLOGY;
DRUG PRESCRIBING;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR EFFECT;
CLINICAL TRIAL;
DRUG EFFECT;
DRUG SELECTIVITY;
GASTROINTESTINAL SYMPTOM;
HUMAN;
INFLAMMATORY DISEASE;
PRIORITY JOURNAL;
SHORT SURVEY;
THROMBOSIS;
ANIMALS;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
CAROTID ARTERY INJURIES;
CELL DIVISION;
CLINICAL TRIALS;
CYCLOOXYGENASE 1;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITORS;
CYCLOOXYGENASE INHIBITORS;
EPOPROSTENOL;
HOMEOSTASIS;
HUMANS;
ISOENZYMES;
LACTONES;
MEMBRANE PROTEINS;
MICE;
MUSCLE, SMOOTH, VASCULAR;
MYOCARDIAL INFARCTION;
NAPROXEN;
PLATELET ACTIVATION;
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;
RECEPTORS, EPOPROSTENOL;
RECEPTORS, PROSTAGLANDIN;
RECEPTORS, THROMBOXANE;
SULFONES;
THROMBOXANE A2;
|
|
EID: 0037134010
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.1071702 Document Type: Short Survey |
|
Times cited : (88)
|
|
References (14)
|
